Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
Condition: Pulmonary Disease, Chronic Obstructive Interventions: Drug: Tiotropium+Olodaterol; Device: Spiolto Respimat; Drug: Long-acting muscarinic antagonists (LAMAs); Drug: Long-acting β2-agonists (LABAs) Sponsor: Boehringer Ingelheim Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Obstructive Pulmonary | Health Insurance | Insurance | Research | Spiriva | Study | Taiwan Health | Tiotropium